CONCLUSIONS: Our findings indicate a possible connection between the patients’ neurodegenerative conditions and GALC defects, including disease-associated polymorphisms and silent variants. Additional genetic alterations affecting sphingolipid and glycosaminoglycan metabolism may act as contributing factors.
